title: Peroxynitrite decomposition with FeTMPyP improves plasma-induced vascular dysfunction and infarction during mild but not severe hyperglycemic stroke.
abstract: We investigated mechanisms by which circulating factors during hyperglycemic (HG) stroke affect cerebrovascular function and the role of peroxynitrite in stroke outcome. Middle cerebral arteries (MCAs) were isolated from male Wistar rats and perfused with plasma from rats that were hyperglycemic for 5 to 6 days by streptozotocin and underwent either MCA occlusion (HG MCAO) or Sham surgery (HG Sham) compared with MCA perfused with physiologic saline (No plasma). Myogenic responses and endothelial function were compared in untreated MCA (n=8/group) or with inhibitors of NADPH oxidase (apocynin; n=8), peroxynitrite (FeTMPyP; n=8) or endothelin-1 (ET-1)(A) (BQ-123; n=8). Finally, animals were treated in vivo before reperfusion after mild (<68% cerebral blood flow (CBF) decrease) or severe (>68% CBF decrease) MCAO with FeTMPyP (n=12) or vehicle (n=12) and CBF and infarction measured. The HG MCAO plasma increased tone in MCA versus No plasma (P<0.05) that was reversed by FeTMPyP, but not by apocynin or BQ-123. The HG Sham plasma also increased tone in MCA (P<0.05) that was reversed by BQ-123 only. In vivo, FeTMPyP was neuroprotective during mild, but not severe ischemia. These results show that circulating factors in plasma can affect cerebrovascular function through peroxynitrite generation and ET-1. In addition, peroxynitrite decomposition improves stroke outcome acutely during mild, but not severe HG ischemia.
authors.affiliation: Departments of Neurology, Obstetrics, Gynecology and Reproductive Sciences, and Pharmacology, University of Vermont College of Medicine, Burlington, VT, USA.
authors.forename: Sara Morales
authors.initials: SM
authors.lastname: Palomares
authors.forename: Ira
authors.initials: I
authors.lastname: Gardner-Morse
authors.forename: Julie G
authors.initials: JG
authors.lastname: Sweet
authors.forename: Marilyn J
authors.initials: MJ
authors.lastname: Cipolla
mesh_terms: D000098:Acetophenones / Q000494:pharmacology; D000818:Animals; D020520:Brain Infarction / Q000097:blood / Q000150:complications; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006943:Hyperglycemia / Q000097:blood* / Q000150:complications; D008297:Male; D008665:Metalloporphyrins / Q000494:pharmacology*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D030421:Peroxynitrous Acid / Q000037:antagonists & inhibitors*; D051381:Rats; D017208:Rats, Wistar; D012720:Severity of Illness Index; D020521:Stroke / Q000097:blood* / Q000150:complications
chemical_list: C492721:5,10,15,20-tetrakis(N-methyl-4'-pyridyl)porphyrinato-iron(III); D000098:Acetophenones; D004791:Enzyme Inhibitors; D008665:Metalloporphyrins; D018696:Neuroprotective Agents; D030421:Peroxynitrous Acid; C056165:acetovanillone